Search
  1. Home
  2. Southern Africa
  3. South Africa
  • News

Glaxo again under fire from AIDS activists

    JOHANNESBURG

    The Network of AIDS Communities in South Africa (NetCom SA) says multinational drug giant GlaxoSmithKline's (GSK) past pricing policies have limited people's access to AIDS drugs in developing countries.

    Glaxo recently granted its 5th voluntary license to Indian drug manufacturer Cipla to produce generic versions of its patented AIDS drugs for use in Africa.

    However, NetCom SA claimed in a statement that since 2001, when GSK signed its first licensing agreement with South Africa's Aspen Phamacare, the production of life-saving generic AIDS drugs had moved at a "glacial pace" in hard-hit African countries.

    Vowing to renew their call to Glaxo to address its past wrongdoing, NetCom executive director Swazi Hlubi said: "GSK's actions on voluntary licensing are once again too little, too late."

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join